Results 131 to 140 of about 3,904 (178)

Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary center. [PDF]

World J Gastrointest Pharmacol Ther
Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A.   +10 more
europepmc   +1 more source

Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States. [PDF]

Arthritis Res Ther
Magrey M, Gianfrancesco MA, Fallon L, Yndestad A, Vranic I, Wei Y, Ling YL, Gruben D, Curtis JR.   +8 more
europepmc   +1 more source

Endoscopic Outcomes of Risankizumab in Crohn's Disease: A Real-World Analysis of Terminal Ileal Lesions. [PDF]

Inflamm Intest Dis
Uchiyama K, Takagi T, Obata R, Murakami E, Asaeda K, Kajiwara-Kubota M, Hotta Y, Tanaka M, Inoue K, Omatsu T, Katada K, Naito Y.   +11 more
europepmc   +1 more source

Risankizumab for psoriasis

, 2020
openaire   +1 more source

Subacute Annular Pustular Psoriasis with Flexural Accentuation: Dramatic Response to Risankizumab.

Acta Derm Venereol
Ong KY, Lim DZJ, Lim JH, Chio MT, Chong WS.   +4 more
europepmc   +1 more source

Risankizumab for psoriasis.

Australian prescriber
openaire   +1 more source